Recent advances in the use of therapeutic cancer vaccines in genitourinary malignancies

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Expert Opinion on Biological Therapy

• Publication date

  2014-11-08

• Fields of study

  Medicine

• Identifiers
  DOI 10.1517/14712598.2014.955010PMID 25212872PMCID PMC8262094
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A Randomized Phase II Trial of Sipuleucel-T with Concurrent versus Sequential Abiraterone Acetate plus Prednisone in Metastatic Castration-Resistant Prostate Cancer

  2015cited by this paper
• Prospect: A randomized double-blind phase 3 efficacy study of PROSTVAC-VF immunotherapy in men with asymptomatic/minimally symptomatic metastatic castration-resistant prostate cancer.

  2015cited by this paper
• A combination trial of vaccine plus ipilimumab in metastatic castration-resistant prostate cancer patients: immune correlates

  2014cited by this paper
• Orchestrating immune check-point blockade for cancer immunotherapy in combinations.

  2014cited by this paper
• ADAPT: An ongoing international phase III randomized trial of autologous dendritic cell immunotherapy (AGS-003) plus standard treatment in advanced renal cell carcinoma (RCC).

  2014cited by this paper
• Identification by digital immunohistochemistry of intratumoral changes of immune infiltrates after vaccine in the absence of modifications of PBMC immune cell subsets

  2014cited by this paper
• Trends in stage‐specific incidence rates for urothelial carcinoma of the bladder in the United States: 1988 to 2006

  2014cited by this paper
• Inhibition of PD-L1 by MPDL3280A and clinical activity in pts with metastatic urothelial bladder cancer (UBC).

  2014cited by this paper
• A randomized, prospective, phase II study to determine the efficacy of BCG given in combination with panvac versus BCG alone in adults with high grade non-muscle invasive bladder cancer who failed at least one induction course of BCG.

  2014cited by this paper
• CTLA-4 and PD-1/PD-L1 Blockade: New Immunotherapeutic Modalities with Durable Clinical Benefit in Melanoma Patients

  2013cited by this paper
• Modified Vaccinia virus Ankara: innate immune activation and induction of cellular signalling.

  2013cited by this paper
• A Randomized Phase II Study of Immunization With Dendritic Cells Modified With Poxvectors Encoding CEA and MUC1 Compared With the Same Poxvectors Plus GM-CSF for Resected Metastatic Colorectal Cancer

  2013cited by this paper
• Alpha emitter radium-223 and survival in metastatic prostate cancer.

  2013cited by this paper
• Phase I study of intraprostatic vaccine administration in men with locally recurrent or progressive prostate cancer

  2013cited by this paper
• Randomized phase II trial evaluating the optimal sequencing of sipuleucel-T and androgen-deprivation therapy (ADT) in patients (pts) with biochemically recurrent prostate cancer (BRPC).

  2013cited by this paper
• A multi-peptide, dual-adjuvant telomerase vaccine (GX301) is highly immunogenic in patients with prostate and renal cancer

  2013cited by this paper
• Lapatinib and doxorubicin enhance the Stat1‐dependent antitumor immune response

  2013cited by this paper
• A new age for vaccine therapy in renal cell carcinoma.

  2013cited by this paper
• Radiation and immunotherapy: a synergistic combination.

  2013cited by this paper
• Lower baseline prostate-specific antigen is associated with a greater overall survival benefit from sipuleucel-T in the Immunotherapy for Prostate Adenocarcinoma Treatment (IMPACT) trial.

  2013cited by this paper
• HLA-restricted NY-ESO-1 peptide immunotherapy for metastatic castration resistant prostate cancer

  2013cited by this paper
• Prostate cancer vaccines

  2013cited by this paper
• AE37 peptide vaccination in prostate cancer: a 4-year immunological assessment updates on a phase I trial

  2013cited by this paper
• Attacking malignant cells that survive therapy

  2013cited by this paper
• Single-dose cyclophosphamide synergizes with immune responses to the renal cell cancer vaccine IMA901

  2013cited by this paper
• Abiraterone in metastatic prostate cancer without previous chemotherapy.

  2013cited by this paper
• A randomized phase II trial of sipuleucel-T with concurrent or sequential abiraterone acetate (AA) plus prednisone (P) in metastatic castrate-resistant prostate cancer (mCRPC).

  2013cited by this paper
• Prolonged survival with personalized immunotherapy (AGS-003) in combination with sunitinib in unfavorable risk metastatic RCC (mRCC).

  2013cited by this paper
• Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival

  2012cited by this paper
• Radiotherapy increases the permissiveness of established mammary tumors to rejection by immunomodulatory antibodies.

  2012cited by this paper
• Increased survival with enzalutamide in prostate cancer after chemotherapy.

  2012cited by this paper
• Current Treatment Considerations in Metastatic Renal Cell Carcinoma

  2012influential reference
• Consequence of dose scheduling of sunitinib on host immune response elements and vaccine combination therapy

  2012cited by this paper
• Sipuleucel-T immune parameters correlate with survival: an analysis of the randomized phase 3 clinical trials in men with castration-resistant prostate cancer

  2012cited by this paper
• Oncogenic BRAF(V600E) Promotes Stromal Cell-Mediated Immunosuppression Via Induction of Interleukin-1 in Melanoma

  2012cited by this paper
• Cancer peptide vaccine therapy developed from oncoantigens identified through genome-wide expression profile analysis for bladder cancer.

  2012cited by this paper
• Technologies for enhanced efficacy of DNA vaccines

  2012cited by this paper
• Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial.

  2012cited by this paper
• Immune responses in prostate tumor tissue following neoadjuvant sipuleucel-T in patients with localized prostate cancer.

  2012cited by this paper
• Combining immunological and androgen-directed approaches: an emerging concept in prostate cancer immunotherapy

  2012cited by this paper
• Integration of immunotherapy into the management of advanced prostate cancer.

  2012cited by this paper
• The tipping point for combination therapy: cancer vaccines with radiation, chemotherapy, or targeted small molecule inhibitors.

  2012cited by this paper
• Neoadjuvant sipuleucel-T in localized prostate cancer: Effects on immune cells within the prostate tumor microenvironment.

  2012cited by this paper
• Platinum-based drugs disrupt STAT6-mediated suppression of immune responses against cancer in humans and mice.

  2011cited by this paper
• A Pilot Study of MUC-1/CEA/TRICOM Poxviral-Based Vaccine in Patients with Metastatic Breast and Ovarian Cancer

  2011cited by this paper
• Abiraterone and increased survival in metastatic prostate cancer.

  2011cited by this paper
• Tumor vaccination using messenger RNA: prospects of a future therapy.

  2011cited by this paper
• Bacillus Calmette–Guérin treatment of non‐muscle invasive bladder cancer

  2011cited by this paper
• A phase II study of the cancer vaccine TG4010 alone and in combination with cytokines in patients with metastatic renal clear-cell carcinoma: clinical and immunological findings

  2011cited by this paper
• Sipuleucel-T immunotherapy for castration-resistant prostate cancer.

  2010influential reference
• Improved survival with ipilimumab in patients with metastatic melanoma.

  2010cited by this paper
• Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer.

  2010cited by this paper
• Tumor cell death and ATP release prime dendritic cells and efficient anticancer immunity.

  2010cited by this paper
• Cancer Statistics, 2010

  2010cited by this paper
• Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.

  2010cited by this paper
• 5T4-modified vaccinia Ankara: progress in tumor-associated antigen-based immunotherapy

  2010cited by this paper
• Vaccination of Metastatic Renal Cancer Patients with MVA-5T4: A Randomized, Double-Blind, Placebo-Controlled Phase III Study

  2010cited by this paper
• Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer

  2010cited by this paper
• Tumor Regression and Growth Rates Determined in Five Intramural NCI Prostate Cancer Trials: The Growth Rate Constant as an Indicator of Therapeutic Efficacy

  2010cited by this paper
• Regulatory T-Cell–Mediated Attenuation of T-Cell Responses to the NY-ESO-1 ISCOMATRIX Vaccine in Patients with Advanced Malignant Melanoma

  2009cited by this paper
• Vaccination of Renal Cell Cancer Patients With Modified Vaccinia Ankara Delivering the Tumor Antigen 5T4 (TroVax) Alone or Administered in Combination With Interferon-α (IFN-α): A Phase 2 Trial

  2009cited by this paper
• Prostvac-VF: a vector-based vaccine targeting PSA in prostate cancer

  2009cited by this paper
• Phase II trial of Modified Vaccinia Ankara (MVA) virus expressing 5T4 and high dose Interleukin-2 (IL-2) in patients with metastatic renal cell carcinoma

  2009cited by this paper
• Sunitinib Mediates Reversal of Myeloid-Derived Suppressor Cell Accumulation in Renal Cell Carcinoma Patients

  2009cited by this paper
• A change of strategy in the war on cancer

  2009cited by this paper
• Sequential therapy in renal cell carcinoma

  2009cited by this paper
• Vaccination of Patients With Metastatic Renal Cancer With Modified Vaccinia Ankara Encoding the Tumor Antigen 5T4 (TroVax) Given Alongside Interferon-α

  2009cited by this paper
• Pilot Study of Vaccination with Recombinant CEA-MUC-1-TRICOM Poxviral-Based Vaccines in Patients with Metastatic Carcinoma

  2008cited by this paper
• Sunitinib Reverses Type-1 Immune Suppression and Decreases T-Regulatory Cells in Renal Cell Carcinoma Patients

  2008cited by this paper
• Expanded phase I combination trial of GVAX immunotherapy for prostate cancer and ipilimumab in patients with metastatic hormone-refractory prostate cancer (mHPRC)

  2008cited by this paper
• Synergizing radiation therapy and immunotherapy for curing incurable cancers. Opportunities and challenges.

  2008cited by this paper
• Immune Responses Detected in Urothelial Carcinoma Patients After Vaccination With NY-ESO-1 Protein Plus BCG and GM-CSF

  2008cited by this paper
• Phase I Immunotherapeutic Trial with Long Peptides Spanning the E6 and E7 Sequences of High-Risk Human Papillomavirus 16 in End-Stage Cervical Cancer Patients Shows Low Toxicity and Robust Immunogenicity

  2008cited by this paper
• Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): a literature review.

  2008cited by this paper
• DC-based cancer vaccines.

  2007cited by this paper
• Early effects of pharmacological androgen deprivation in human prostate cancer

  2007cited by this paper
• PANVAC™-VF: poxviral-based vaccine therapy targeting CEA and MUC1 in carcinoma

  2007influential reference
• Clinical safety of a viral vector based prostate cancer vaccine strategy.

  2007cited by this paper
• A combination of chemoimmunotherapies can efficiently break self-tolerance and induce antitumor immunity in a tolerogenic murine tumor model.

  2007cited by this paper
• Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy

  2006cited by this paper
• Sipuleucel-T

  2006cited by this paper
• A randomized phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer.

  2006cited by this paper
• Cancer-testis antigen expression in bladder cancer.

  2005cited by this paper
• Cancer-testis antigen expression in bladder cancer.

  2005cited by this paper
• Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.

  2004cited by this paper
• Augmentation of T Cell Levels and Responses Induced by Androgen Deprivation1

  2004cited by this paper
• Amplification of the lytic potential of effector/memory CD8+ cells by vector-based enhancement of ICAM-1 (CD54) in target cells: implications for intratumoral vaccine therapy

  2004cited by this paper
• Phase I immunotherapy with a modified vaccinia virus (MVA) expressing human MUC1 as antigen‐specific immunotherapy in patients with MUC1‐positive advanced cancer

  2003influential reference
• Cancer immunoediting: from immunosurveillance to tumor escape

  2002influential reference
• MUC1 mucin and trefoil factor 1 protein expression in renal cell carcinoma: correlation with prognosis.

  2002cited by this paper
• Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma.

  2002cited by this paper
• Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells.

  2000cited by this paper
• Vaccination for Malignant Melanoma: Recent Developments

  2000cited by this paper
• Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma

  1998cited by this paper
• Human tumor antigens recognized by T lymphocytes

  1996cited by this paper
• Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy.

  1995cited by this paper
• Genetic instability and tumor cell variation: implications for immunotherapy.

  1995cited by this paper
• Specific association of human telomerase activity with immortal cells and cancer.

  1994cited by this paper
• Tolerance, danger, and the extended family.

  1994cited by this paper
• Tumor antigens recognized by T lymphocytes.

  1994cited by this paper

• Glycan-based therapeutic approaches for bladder cancer: Overcoming clinical barriers.

  2025cites this paper
• Recent Advances of Neoadjuvant Immunotherapy for Urothelial Bladder Cancer

  2024cites this paper
• Molecular mechanisms augmenting resistance to current therapies in clinics among cervical cancer patients

  2023cites this paper
• Landscape and perspectives of macrophage -targeted cancer therapy in clinical trials

  2022cites this paper
• Cancer Vaccines for Genitourinary Tumors: Recent Progresses and Future Possibilities

  2021influential citation
• Mycobacterium phlei cell wall-nucleic acid complex in the treatment of nonmuscle invasive bladder cancer unresponsive to bacillus Calmette-Guerin

  2016cites this paper